U.S. Government Accountability Office, 2025-04-09: GAO report stating that cisplatin and carboplatin each had five manufacturers when the 2023 shortages began, that one firm held most of the cisplatin market, and that a single plant closure for quality problems triggered the shortage; cisplatin resolved June 2024, carboplatin still short as of Dec 2024.
Both drugs had five manufacturers when the shortages occurred, with a majority share of the cisplatin market concentrated with one manufacturer, according to FDA officials.
pp. 25-26
U.S. Government Accountability Office, 2025-04-09: GAO report stating that cisplatin and carboplatin each had five manufacturers when the 2023 shortages began, that one firm held most of the cisplatin market, and that a single plant closure for quality problems triggered the shortage; cisplatin resolved June 2024, carboplatin still short as of Dec 2024. Study type: other.
